Tarlatamab Prolongs OS Over Chemotherapy Among Patients with SCLC Whose Disease Had Progressed During or After Platinum-Based Chemotherapy By Ogkologos - June 16, 2025 544 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the DeLLphi-304 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Welcomes European Parliament (EP) Draft Report on Psychosocial Risks at Work (PSR) as a Critical Opportunity to Protect the Wellbeing of the Cancer... FDA Approves Nivolumab with Chemotherapy for Previously Untreated Hodgkin Lymphoma 2026 ESMO Breast Cancer Award Recipient Announced MOST POPULAR FDA Grants Accelerated Approval to Tovorafenib for Patients with Relapsed or... May 2, 2024 Bra Straps with Disappearing Message Remind Women to Check Their Breasts... April 12, 2021 Following Abnormal Cancer Screening Results, Multi-Level Reminders May Increase Follow-Up December 22, 2023 NExT: Advancing Promising Cancer Therapies from the Lab to Clinical Trials June 29, 2018 Load more HOT NEWS What to Know About At-Home DNA Tests for Detecting Cancer Risk First-Line Triplet Combination of Zolbetuximab, mFOLFOX6 and Nivolumab Supports Targeting CLDN18.2... Fake Amazon Delivery Driver Attempts to Steal Elderly Woman’s Cancer Drugs Breakthrough SARS-CoV-2 Infection Following COVID-19 Vaccination in Patients with Cancer
